therapeutic cancer vaccine to be tested in humans

RESEARCH & DEVELOPMENT Therapeutic cancer vaccine to be tested in humans ImClone Systems Incorporated have announced that their novel therapeutic cancer vaccine, LuVax®, is entering its first clinical trial. The phase I study will assess the safety of the vaccine in patients treated for small cell lung cancer. The vaccine is a monoclonal anti-idiotypic antibody which mimics GD3, an antigen found on the surface of certain tumour cells, including those of small cell lung cancers. The vaccine elicits an immune response that may inhibit rapid growth of GD3-containing cells and, thereby, prevent relapse after chemotherapy. This is the first clinical trial of a vaccine against lung cancer. Small cell lung cancer is the fifth leading cause of cancer-related deaths and it affects 40 000 people in the US annually. - Media release ISSN 0156·270319310424-00131$1.000 Adls International Ltd Il001 9 1176 13 INPHARMA e 24 Apr 1993

Upload: trinhxuyen

Post on 22-Mar-2017

212 views

Category:

Documents

0 download

Report

Download

Embed Size (px):

TRANSCRIPT

RESEARCH & DEVELOPMENT

Therapeutic cancer vaccine to be tested in humans

ImClone Systems Incorporated have announced that their novel therapeutic cancer vaccine, LuVax®, is entering its first clinical trial. The phase I study will assess the safety of the vaccine in patients treated for small cell lung cancer.

The vaccine is a monoclonal anti-idiotypic antibody which mimics GD3, an antigen found on the surface of certain tumour cells, including those of small cell lung cancers. The vaccine elicits an immune response that may inhibit rapid growth of GD3-containing cells and, thereby, prevent relapse after chemotherapy. This is the first clinical trial of a vaccine against lung cancer. Small cell lung cancer is the fifth leading cause of cancer-related deaths and it affects 40 000 people in the US annually. - Media release

ISSN 0156·270319310424-00131$1.000 Adls International Ltd

Il001 9 1176

INPHARMAe 24 Apr 1993

VACCINE PART.2 PART - NPOJIPVACCINE PART.2 VACCINE PART.2 VACCINE PART.2 VACCINE PART.2 VACCINE PART.2 VACCINE PART.2 VACCINE PART.2 VACCINE PART.2 VACCINE PART.2 PART.2 集特 Check-up

Dendritic cell-based therapeutic vaccine approaches Felipe Garcia 1Hospital Clinic-IDIBAPS-HIVACAT, University of Barcelona. Barcelona.Spain 1Hospital

HPV - Therapeutic Vaccine

Two Vaccines for Induce a B-Cell- Mediated Immune ResponseABSTRACT Staphylococcus aureus causes severe disease in humans for which no li-censed vaccine exists. A novel S. aureus vaccine

Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine ...²¨부13... · 2019-03-20 · HPV vaccine that could induce more potent anti-HPV T-cell response

Vaccine Education and esearch - Fondation Mérieux...e-learning software (Rise Articulate) –Vaccine fundamentals –Vaccine preventable diseases –Vaccine safety –Vaccine hesitancy

Vaccine Storage Vaccine

Diagnostic & Therapeutic Institute for Gastrointestinal ... · Gastric adenocarcinoma is the third leading cause of cancer related death among humans. spray to achieve Approximately

VISITOR’S AWARDS · vaccine and a therapeutic antibody against anthrax. Visitor’s Award for Research, 2016 : Molecular Parasitology Group of Jawaharlal Nehru University for pioneering